SCHEMBL4407308

SCHEMBL4407308

Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NC(Cn1cc(S(N)(=O)=O)c2ccccc21)C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 16/20 0.60
NR3C2 P08235 14/20 0.60
PGR P06401 9/20 0.59
CYP3A4 P08684 3/20 0.59
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
CCR10 P46092 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405347 0.89 NR3C1 (0.58) NR3C1NR3C2PGRCYP3A4LMNA
SCHEMBL4066789 0.89 NR3C1 (0.59) NR3C1NR3C2PGRCYP3A4LMNA
SCHEMBL4065751 0.89 NR3C1 (0.75) NR3C1NR3C2PGRCYP3A4
SCHEMBL4069539 0.88 NR3C1 (0.63) NR3C1NR3C2PGRCYP3A4CCR10
SCHEMBL13810710 0.88 NR3C1 (0.59) NR3C1NR3C2PGRCYP3A4CCR10
SCHEMBL4066578 0.87 NR3C1 (0.57) NR3C1NR3C2PGRCYP3A4CCR10
SCHEMBL4069496 0.85 NR3C1 (0.56) NR3C1NR3C2PGRCYP3A4LMNA
SCHEMBL4068678 0.85 NR3C1 (0.58) NR3C1NR3C2PGRCYP3A4MAPT
SCHEMBL4077768 0.85 NR3C1 (0.55) NR3C1NR3C2PGRCYP3A4CCR10
SCHEMBL4071698 0.85 NR3C1 (0.57) NR3C1NR3C2PGRCYP3A4CCR10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US claimed
EP-1836166-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-09-26 EP claimed
US-20060189646-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-08-24 US claimed
WO-2006071609-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-07-06 WO claimed
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-20060189646-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189646-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof NR3C1, NR3C2, MC2R NR3C1 1/4885NR3C2 2/4885PGR 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.